BioRestorative Therapies, Inc.
NASDAQ Capital MarketTotal Valuation
BioRestorative Therapies, Inc. carries a market capitalization of 3.56M, placing it among publicly traded companies globally. Its enterprise value stands at -364,533.90, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.56M |
| Enterprise Value | -364,533.90 |
Share Statistics
BioRestorative Therapies, Inc. currently has 25.48M shares outstanding.
| Shares Outstanding | 25.48M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 9.02, and the price-to-book ratio stands at -0.02.
| PE Ratio | N/A |
| PS Ratio | 9.02 |
| PB Ratio | -0.02 |
| P/TBV Ratio | 1.28 |
| P/FCF Ratio | -0.27 |
| P/OCF Ratio | -0.27 |
Enterprise Valuation
| EV / Sales | 38.19 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
BioRestorative Therapies, Inc. maintains a current ratio of 2.35, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.35 |
| Quick Ratio | 2.23 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -147.75 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
BioRestorative Therapies, Inc.'s stock has declined approximately -73.96053% over the past 52 weeks. The 50-day moving average sits at 0.31, while the 200-day moving average is 0.80.
| Beta (5Y) | N/A |
| 52-Week Price Change | -73.96053% |
| 50-Day Moving Average | 0.31 |
| 200-Day Moving Average | 0.80 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, BioRestorative Therapies, Inc. generated 357,870.00 in revenue and converted that into -11.06M in net income, yielding earnings per share of -0.93. EBITDA reached -14.01M, while operating income came in at -14.23M.
| Revenue | 357,870.00 |
| Gross Profit | 329,550.00 |
| Operating Income | -14.23M |
| Pretax Income | -11.06M |
| Net Income | -11.06M |
| EBITDA | -14.01M |
| EBIT | -14.23M |
| Earnings Per Share (EPS) | -0.93 |
Balance Sheet
Total book value stands at -172.07M, with working capital of 2.19M providing operational flexibility.
| Cash & Cash Equivalents | 3.59M |
| Total Debt | N/A |
| Net Debt | -3.11M |
| Equity (Book Value) | -172.07M |
| Book Value Per Share | -14.51 |
| Working Capital | 2.19M |
Cash Flow
BioRestorative Therapies, Inc. produced -11.82M in operating cash flow over the past twelve months. After subtracting -79,669.00 in capital expenditures, free cash flow totaled -11.90M - equivalent to -1.00 per share.
| Operating Cash Flow | -11.82M |
| Capital Expenditures | -79,669.00 |
| Free Cash Flow | -11.90M |
| FCF Per Share | -1.00 |
Margins
BioRestorative Therapies, Inc. operates with a gross margin of 92.09, reflecting its pricing power and cost economics. The operating margin of -3,975.00 and net profit margin of -3,089.55 provide insight into operational efficiency.
| Gross Margin | 92.09 |
| Operating Margin | -3,975.00 |
| Pretax Margin | -3,089.55 |
| Profit Margin | -3,089.55 |
| EBITDA Margin | -3,916.15 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -192.19 |
| FCF Yield | -363.70 |
Stock Splits
BioRestorative Therapies, Inc.'s most recent stock split took place on October 27, 2021 with a 4000:1 split ratio.
| Last Split Date | 10/27/2021 |
| Split Ratio | 4000:1 |
Scores
BioRestorative Therapies, Inc. posts an Altman Z-Score of -67.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -67.80 |